Commons, Marty

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Freedom Study: Myfortic in Kidney Transplant Patients

Phase 3
Completed
Conditions
First Posted Date
2005-01-13
Last Posted Date
2011-01-31
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
342
Registration Number
NCT00101738
Locations
πŸ‡¬πŸ‡§

Queen Elizabeth Medical Centre, Edgbaston, Birmingham, United Kingdom

πŸ‡¦πŸ‡Ί

Royal Melbourne Hospital, Parkville, Victoria, Australia

πŸ‡¬πŸ‡§

Walsgrave Hospital NHS Trust, Walsgrave, Coventry, United Kingdom

and more 41 locations

Safety and Efficacy of AAE581 in Postmenopausal Women With Osteoporosis

Phase 2
Completed
Conditions
First Posted Date
2005-01-04
Last Posted Date
2012-05-08
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
676
Registration Number
NCT00100607

A Study of the Clinical Safety, Tolerability, and Efficacy of Zoledronic Acid Compared to an Oral Bisphosphonate

Phase 3
Completed
Conditions
First Posted Date
2005-01-04
Last Posted Date
2012-04-27
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
120
Registration Number
NCT00100555
Locations
πŸ‡ΊπŸ‡Έ

St. Luke's Episcopal Hospital Ctr for Ortho. Res. and Education, Houston, Texas, United States

πŸ‡ΊπŸ‡Έ

Univ. of Alabama/Division of Clinical Immunology and Rheumatology, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Denver Arthritis Clinic, Denver, Colorado, United States

and more 14 locations

Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis

Phase 3
Completed
Conditions
First Posted Date
2005-01-04
Last Posted Date
2017-05-17
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
802
Registration Number
NCT00100620
Locations
πŸ‡ΊπŸ‡Έ

McGuire VA Medical Center, Richmond, Virginia, United States

πŸ‡ΊπŸ‡Έ

United Osteoporosis Centers, Gainesville, Georgia, United States

πŸ‡ΊπŸ‡Έ

Center for Education and research on Therapeutics (CERTs) of Musculoskeletal Disorders, Birmingham, Alabama, United States

and more 3 locations

Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

First Posted Date
2004-12-22
Last Posted Date
2012-05-07
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
515
Registration Number
NCT00099944
Locations
πŸ‡ΊπŸ‡Έ

Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

First Posted Date
2004-12-22
Last Posted Date
2012-05-07
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
570
Registration Number
NCT00099866
Locations
πŸ‡©πŸ‡ͺ

Novartis investigative Site, Investigative Sites, Germany

Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
First Posted Date
2004-12-22
Last Posted Date
2012-05-07
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
254
Registration Number
NCT00099931
Locations
πŸ‡©πŸ‡ͺ

Novartis Investigative Site, Investigative Sites, Germany

A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes

Phase 2
Completed
Conditions
First Posted Date
2004-12-22
Last Posted Date
2012-05-02
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
38
Registration Number
NCT00099957
Locations
πŸ‡¨πŸ‡­

Novartis Pharmaceuticals, Basel, Switzerland

A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
First Posted Date
2004-12-22
Last Posted Date
2012-05-02
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
639
Registration Number
NCT00099905
Locations
πŸ‡ΊπŸ‡Έ

Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
First Posted Date
2004-12-22
Last Posted Date
2017-05-17
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
717
Registration Number
NCT00099918
Locations
πŸ‡ΊπŸ‡Έ

Novartis Pharmaceuticals, East Hanover, New Jersey, United States

πŸ‡©πŸ‡ͺ

Novartis Investigative Sites, Investigative Centers, Germany

Β© Copyright 2024. All Rights Reserved by MedPath